Safety and effectiveness of stiripentol in patients with Dravet syndrome: A prospective, 3‐year, postmarketing surveillance study
Developmental Medicine & Child Neurology · 2025
DOI: 10.1111/dmcn.16252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Medicine & Child Neurology, 2025. Verfasst von Yuki Kitamura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Safety Vigilance & Management Department, Reliability & Quality Assurance Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Dioxolanes, Product Surveillance, Postmarketing, Anticonvulsants. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aim
To conduct a postmarketing surveillance study of patients with Dravet syndrome in Japan to investigate the safety and effectiveness of long‐term, real‐world, clinical use of stiripentol (STP).
Method
This prospective study was conducted over 156 weeks in all patients with Dravet syndrome who started STP treatment from its launch in Japan in November 2012 until August 2017. Adverse drug reactions (ADRs) were investigated by degree of seriousness. Effectiveness was determined based on a comprehensive assessment by the physician in charge as well as on the percentage change in the number of seizures from the pretreatment period.
Results
In total, 520 patients (266 males, 254 females; mean age [SD] 10 years 6 months [9 years 10 months]; age range 0–50 years) were included in the safety analysis set, and 515 patients in the effectiveness analysis set. ADRs occurred in 69.2%, including somnolence, decreased appetite, dizziness, in order of frequency. Twelve deaths occurred, the rate of which was not higher than the reported rates. No new safety concerns were identified. The rate of overall improvement (marked or moderate) after 156 weeks or at treatment discontinuation was 37.7%. Decreases in the number of all seizure types over the long term were confirmed.
Interpretation
In real‐world clinical settings, long‐term STP treatment can be safe and effective in patients with Dravet syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Safety Vigilance & Management Department, Reliability & Quality Assurance Division, Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
- Department of Clinical Research, National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.
- Department of Child Neurology, Asahigawaso Rehabilitation and Medical Center, Okayama, Japan.
ORCID-Profile: Yuki Kitamura
Zitieren
APA
Kitamura, Y., Ohyabu, H., Miura, T., Takei-Masuda, N., Matsui, D., Inoue, Y., & Ohtsuka, Y. (2025). Safety and effectiveness of stiripentol in patients with Dravet syndrome: A prospective, 3‐year, postmarketing surveillance study. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.16252
Vancouver
Kitamura Y, Ohyabu H, Miura T, Takei-Masuda N, Matsui D, Inoue Y, et al. Safety and effectiveness of stiripentol in patients with Dravet syndrome: A prospective, 3‐year, postmarketing surveillance study. Developmental Medicine & Child Neurology. 2025. doi:10.1111/dmcn.16252
BibTeX
@article{Kitamura2025,
author = {Kitamura, Yuki and Ohyabu, Hiroaki and Miura, Tatsuo and Takei-Masuda, Naomi and Matsui, Daisuke and Inoue, Yushi and Ohtsuka, Yoko},
title = {Safety and effectiveness of stiripentol in patients with Dravet syndrome: A prospective, 3‐year, postmarketing surveillance study},
journal = {Developmental Medicine & Child Neurology},
year = {2025},
doi = {10.1111/dmcn.16252}
}
EUVIMED